^
    Back
    Association details:
    Biomarker:FGFR1 amplification
    Cancer:Breast Cancer
    Drug:afimoxifene (Selective estrogen receptor modulator)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Res
    Title:

    FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

    Excerpt:
    FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1.
    DOI:
    10.1158/0008-5472.CAN-09-3746